AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CL

Wallace Noel R. sold $29.7M of CL

Wallace Noel R. (Chairman, President & CEO) sold 322,042 shares of COLGATE PALMOLIVE CO (CL) at an average of $92.22 ($91.92–$92.52, $29.70M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · Wallace Noel R.
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence short-term sentiment, but it does not provide new information about earnings, guidance, or business performance.

02

Market read

Traders may monitor CL for sentiment effects from insider selling, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

No 10b5-1 plan details are provided in the text, and insider sales often have non-informational motives; traders should avoid over-weighting without corroborating fundamentals or guidance changes.

Relevance 7/10Novelty 5/10Timing: Form 4 filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05.

Background

The article is a SEC Form 4 insider transaction disclosure for Colgate-Palmolive (CL) by its Chairman, President and CEO.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

Colgate-Palmolive CEO Wallace Noel R. sold 322,042 shares in open-market transactions totaling about $29.7M, per Form 4 filed Aug. 6.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan disclosed and no accompanying operational or guidance change in the text.

Market effects

Sector

Minimal. Large-cap consumer staples insider sales are typically not sector-moving without additional company-specific catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be planned liquidity management rather than a bearish signal, especially given the multi-day execution window.

Key entities

  • issuer
    Colgate-Palmolive Co

    Subject of the Form 4 insider sale disclosure.

  • insider
    Wallace Noel R.

    Chairman, President and CEO who sold 322,042 shares for about $29.7M.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CL insider trading history →

Related articles

$CLMed

BofA raises Colgate-Palmolive stock price target to $105 on earnings

BofA Securities raised its price target for Colgate-Palmolive (NYSE:CL) to $105 from $100, citing strong earnings and updated fiscal 2026 guidance. The company reported Q3 earnings of $0.97 per share, exceeding estimates, with revenue of $5.37 billion. Colgate updated its outlook, expecting 4% to 5% net sales growth and 5% to 7% earnings growth. Analysts from UBS and Wells Fargo also raised their price targets.

investing.com
$CLMedAI 8/10

Wells Fargo raises Colgate-Palmolive stock price target on solid Q3

Wells Fargo raised its price target for Colgate-Palmolive (NYSE:CL) to $95 from $90, citing solid Q3 2026 results. The firm noted strong performance despite macroeconomic challenges and inflation. CL's P/E ratio is 37.77, and it is considered overvalued. Q3 earnings beat expectations with $0.97 EPS on $5.37B revenue. UBS also raised its target to $112, highlighting strong margins.

investing.com
$CLMed

UBS raises Colgate-Palmolive stock price target on margin strength

UBS raised its price target for Colgate-Palmolive (CL) to $112 from $106, citing strong Q3 earnings, revenue, and margins. The company beat EPS estimates and raised 2026 guidance. UBS expects continued sales growth despite inflation and FX headwinds, though the stock is slightly overvalued. CL reported Q3 adjusted EPS of $0.97 on revenue of $5.37B, exceeding expectations.

investing.com
$CLMed

Colgate-Palmolive Co (CL) (Q3 2026) Earnings Call Highlights: Broad-Based Organic

Colgate-Palmolive (CL) reported Q3 2026 earnings, highlighting 6.5% organic growth in Hills pet food and strong volume leverage. CEO Noel Wallace attributed margin gains to pricing, innovation, and ad spend efficiency. CFO Stan Sutula noted material cost headwinds offset by productivity and pricing. Latin America grew 6%, with Brazil up double-digits. US toothpaste showed slight improvement, with more pricing expected.

finance.yahoo.com
$CLHighAI 8/10

Colgate-Palmolive Company Q3 2026 Earnings Call Summary

Colgate-Palmolive reported Q3 2026 earnings, highlighting organic growth in emerging markets and Europe. Gross margin expansion was driven by pricing strategy and manufacturing leverage. The company is transitioning its U.S. go-to-market structure and integrating AI for revenue growth. Hill's Pet Nutrition saw strong performance in high-growth segments.

finance.yahoo.com
$CLHighAI 8/10

Colgate-Palmolive Q3 Earnings Call Highlights

Colgate-Palmolive (CL) reported Q3 earnings, noting elevated commodity and logistics costs. Hill's Pet Nutrition saw 6.5% organic sales growth, driven by cat food and wet food. U.S. toothpaste market share shows early improvement. Latin America grew 6%, with Brazil up double digits. Asia-Pacific rose 5%, led by India. Full-year cost inflation is estimated at $300M. The company plans to provide 2027 guidance in Q1 next year.

finance.yahoo.com